Search

Your search keyword '"Necela, Brian M."' showing total 61 results

Search Constraints

Start Over You searched for: Author "Necela, Brian M." Remove constraint Author: "Necela, Brian M." Database Unpaywall Remove constraint Database: Unpaywall
61 results on '"Necela, Brian M."'

Search Results

1. Higher and Sustained Cell-Mediated Immune Responses after Three Doses of mRNA COVID-19 Vaccine In Patients with Inflammatory Bowel Disease on Anti-TNF Therapy

2. Th17-inducing dendritic cell vaccines stimulate effective CD4 T cell-dependent antitumor immunity in ovarian cancer that overcomes resistance to immune checkpoint blockade

3. Data from Detection of Redundant Fusion Transcripts as Biomarkers or Disease-Specific Therapeutic Targets in Breast Cancer

4. Data from Detection of Redundant Fusion Transcripts as Biomarkers or Disease-Specific Therapeutic Targets in Breast Cancer

5. Supplementary Table 1 from Detection of Redundant Fusion Transcripts as Biomarkers or Disease-Specific Therapeutic Targets in Breast Cancer

6. Supplementary Figure 1 from Detection of Redundant Fusion Transcripts as Biomarkers or Disease-Specific Therapeutic Targets in Breast Cancer

7. Supplementary Table 4 from Detection of Redundant Fusion Transcripts as Biomarkers or Disease-Specific Therapeutic Targets in Breast Cancer

8. Supplementary Table 3 from Detection of Redundant Fusion Transcripts as Biomarkers or Disease-Specific Therapeutic Targets in Breast Cancer

9. Supplementary Table 1 from Detection of Redundant Fusion Transcripts as Biomarkers or Disease-Specific Therapeutic Targets in Breast Cancer

10. Supplementary Table 2 from Detection of Redundant Fusion Transcripts as Biomarkers or Disease-Specific Therapeutic Targets in Breast Cancer

11. Supplementary Table 4 from Detection of Redundant Fusion Transcripts as Biomarkers or Disease-Specific Therapeutic Targets in Breast Cancer

12. Supplementary Table 3 from Detection of Redundant Fusion Transcripts as Biomarkers or Disease-Specific Therapeutic Targets in Breast Cancer

13. Supplementary Figure 1 from Detection of Redundant Fusion Transcripts as Biomarkers or Disease-Specific Therapeutic Targets in Breast Cancer

14. Supplementary Table 2 from Detection of Redundant Fusion Transcripts as Biomarkers or Disease-Specific Therapeutic Targets in Breast Cancer

16. Higher Cell-Mediated Immune Responses in Patients With Inflammatory Bowel Disease on Anti-TNF Therapy After COVID-19 Vaccination

17. Trpc6 Promotes Doxorubicin-Induced Cardiomyopathy in Male Mice With Pleiotropic Differences Between Males and Females

18. Association of Genetic Variants at TRPC6 With Chemotherapy-Related Heart Failure

19. Folate receptor alpha expression associates with improved disease-free survival in triple negative breast cancer patients

21. Chromoanasynthesis is a common mechanism that leads to ERBB2 amplifications in a cohort of early stage HER2+ breast cancer samples

22. Generation of HER2-specific antibody immunity during trastuzumab adjuvant therapy associates with reduced relapse in resected HER2 breast cancer

23. Genome-wide association study of cardiotoxicity in the NCCTG N9831 (Alliance) adjuvant trastuzumab trial

24. Comprehensive Genomic Profiling of a Rare Thyroid Follicular Dendritic Cell Sarcoma

25. Abstract 3377: Simultaneous analysis of the mutational landscape and RNA and protein expression profile of HER2-positive breast cancer using 3D BiologyTM

26. Correction: Corrigendum: Recurrent hormone-binding domain truncated ESR1 amplifications in primary endometrial cancers suggest their implication in hormone independent growth

28. Intrinsic Subtype and Therapeutic Response Among HER2-Positive Breaty st Tumors from the NCCTG (Alliance) N9831 Trial

29. Correction: Corrigendum: Recurrent hormone-binding domain truncated ESR1 amplifications in primary endometrial cancers suggest their implication in hormone independent growth

30. Recurrent hormone-binding domain truncated ESR1 amplifications in primary endometrial cancers suggest their implication in hormone independent growth

31. Assessment of Tumor Heterogeneity, as Evidenced by Gene Expression Profiles, Pathway Activation, and Gene Copy Number, in Patients with Multifocal Invasive Lobular Breast Tumors

32. Abstract P6-07-03: An exhaustive algorithm for detecting copy number aberrations and large structural variants in whole-genome mate-pair sequencing data

33. Correction: Folate Receptor-α (FOLR1) Expression and Function in Triple Negative Tumors

34. MEN1 Mutations in Hürthle Cell (Oncocytic) Thyroid Carcinoma

35. Folate Receptor-α (FOLR1) Expression and Function in Triple Negative Tumors

36. Clinical and Molecular Features of Hürthle Cell Carcinoma of the Thyroid

37. An exhaustive algorithm for detecting copy number aberrations and large structural variants in whole-genome, mate-pair sequencing data.

39. RNA Sequencing Identifies Multiple Fusion Transcripts, Differentially Expressed Genes, and Reduced Expression of Immune Function Genes in BRAF (V600E) Mutant vs BRAF Wild-Type Papillary Thyroid Carcinoma

40. Gene Expression, Single Nucleotide Variant and Fusion Transcript Discovery in Archival Material from Breast Tumors

41. An Integrated Model of the Transcriptome of HER2-Positive Breast Cancer

42. Increased expression of folate receptor-α (FRA) in triple-negative breast cancer: A potential therapeutic target.

44. Detection of Redundant Fusion Transcripts as Biomarkers or Disease-Specific Therapeutic Targets in Breast Cancer

45. Abstract 4926: Modeling the transcriptome landscape of HER2+ breast cancer

46. Deep Sequence Analysis of Non-Small Cell Lung Cancer: Integrated Analysis of Gene Expression, Alternative Splicing, and Single Nucleotide Variations in Lung Adenocarcinomas with and without Oncogenic KRAS Mutations

48. A novel bioinformatics pipeline for identification and characterization of fusion transcripts in breast cancer and normal cell lines

Catalog

Books, media, physical & digital resources